Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Studied

Two randomized, double-blind trials compared long-acting CJC-1295 with placebo, measuring growth hormone, IGF-I and drug-processing characteristics.

Who / model

Healthy adults aged 21–61 were studied for 28 and 49 days. The abstract does not report participant numbers.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

After a single injection, average growth hormone rose 2- to 10-fold for at least six days and IGF-I rose 1.5- to 3-fold for 9–11 days. After repeated administration, IGF-I remained above baseline for up to 28 days. No serious adverse reactions were reported.

Limits

No author-stated limitations were available in the abstract. The reported endpoints were hormone levels and pharmacokinetics, not demonstrated muscle gain or recovery benefits.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary